Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vurolenatide - 9 Meters Biopharma

Next Previous
X
Search
Drug Profile

Vurolenatide - 9 Meters Biopharma

Alternative Names: GLP-1-XTEN; Long acting GLP-1; NB-1001; NM-002 - 9 Meters Biopharma; XTEN™-GLP-1

Latest Information Update: 21 Sep 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amunix
  • Developer 9 Meters Biopharma; Naia Limited
  • Class Antihyperglycaemics; Glucagon-like peptides; Recombinant fusion proteins
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Short bowel syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 21 Sep 2023 Discontinued - Phase-III for Short bowel syndrome (In adults) in USA (SC)
  • 27 Jun 2023 Vurolenatide is available for licensing as of 28 Mar 2023
  • 31 May 2023 9 Meters Biopharma plans a phase II trial for Short Bowel Syndrome

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top